Sanofi Aventis: The latest figures, news and market research on Sanofi Aventis

Turnover: 42.997 billion USD (2022)

Country: France

A French pharmaceutical company of international stature

Sanofi plans to spin off its Consumer Healthcare business in 2024 28/10/2023

Year of separate listing of Sanofi's Consumer Healthcare Division: 2024
Sanofi envisages savings of: up to 2 billion euros between 2024 and the end of 2025
Presence of Sanofi Consumer Healthcare Division: 150 countries, more than 11,000 employees

Sanofi to spin off its consumer healthcare division and float it on the stock market 27/10/2023

Sanofi is a French pharmaceutical company
The Consumer Healthcare division has over 11,000 employees in 150 countries.
The demerger of Consumer Healthcare will take place in the fourth quarter of 2024 at the earliest.
This division accounts for just over 10% of Group sales.
In 2022, the Consumer Healthcare division generated 5.1 billion euros of Sanofi's 43 billion euros in sales.
The Consumer Healthcare division posted growth of 13.7% in 2022.
By 2021, the global consumer healthcare market will be worth over €180 billion.
The market share of Haleon, the world leader in consumer healthcare, is estimated at 6% in 2021.
The over-the-counter segment accounts for 90 billion euros, vitamins, minerals and supplements for 50 billion euros, and oral care for almost 30 billion euros.
Its Dupixent sales approach 11 billion euros in annual sales.
Beyfortus vaccine is currently marketed in 4 countries, including France.

Sanofi inaugurates Europe's largest vaccine plant at Val-de-Reuil 07/09/2023

Sanofi's vaccine plant in Val-de-Reuil celebrated its 50th anniversary.
Sanofi has invested 250 million euros in two modernization/expansion projects at the plant, which employs 2,200 people.
It ships 600 million doses of vaccines worldwide every year.
Sanofi has set up a new influenza vaccine production unit, at a cost of 200 million euros.
Over the past ten years, Sanofi has invested 600 million euros in Val-de-Reuil.
Sanofi plans to double sales of its vaccines division between 2018 and 2030, to more than 10 billion euros a year.

Sanofi invests $250 million in flu vaccines in France | Sanofi invests $250 million in flu vaccines in France 07/09/2023

Sanofi is the world's fourth-largest vaccines company
Sanofi invests 250 million euros in its Val-de-Reuil site, Europe's largest vaccine production facility
Sanofi has 11 vaccine plants
50% of Sanofi's production is concentrated in influenza.
Sanofi increases influenza vaccine production capacity by 40%
Sanofi's Efluelda vaccine is recommended for the elderly and launched in 18 countries, including 11 where it has been recommended by health authorities.
Sanofi has invested over 600 million euros in its Val-de-Reuil site over the past ten years.

Sanofi gains a foothold in the obesity market with biotech Adocia 10/07/2023

Appetite suppressants derived from antidiabetics are an emerging market
. Industry giants such as American Lilly and Danish Novo Nordisk are already involved in this market.
Sanofi paid 10 million for the exclusive right to negotiate a worldwide partnership for Adocia's M1Pram rapid insulin.
Adocia's M1Pram rapid insulin is special in that it makes you lose weight instead of gaining it.
The potential market for appetite suppressants derived from antidiabetics is estimated at several tens of billions of dollars a year.
Sanofi is a specialist in type 1 diabetes, and M1Pram could benefit obese patients suffering from this type of diabetes - around 5% of type 2 diabetics.
Phase 2 clinical results for M1Pram showed exceptional weight loss with good glycemic control in overweight and obese type 1 diabetics.
The population that could benefit from M1Pram is estimated at nearly 40 million people worldwide, representing a potential market worth several billion dollars.

Sanofi finally has its Covid-19 vaccine 13/11/2022

Doses ready for distribution
The French laboratory has accepted the dominance of the RNA vaccine and the American Moderna and German BioNTech
The recombinant protein technology used in its VidPrevtyn Beta will make it possible to vaccinate populations in regions where the cold chain is difficult to maintain

DUNS: 403335904

Legal Name: SANOFI-AVENTIS FRANCE

Address: 82 AV RASPAIL , 94250 GENTILLY

Number of employees: Entre 2 000 et 4 999 salariés (2020)

Capital: 645 777 EUR

Financial Data:

Year	2021	2020	2019	2018	2017	2016	2015
Turnover	1 580 000 000	1 743 000 000	1 795 000 000	1 981 000 000	2 123 000 000	1 837 000 000	1 937 000 000
Gross margin (€)	777 000 000	805 000 000	3 079 000 000	862 000 000	3 482 000 000	3 141 000 000	-
EBITDA (€)	201 000 000	207 000 000	104 000 000	88 000 000	127 000 000	3 867 000 000	-
Operating profit (€)	175 000 000	186 000 000	174 000 000	88 000 000	163 000 000	245 000 000	-
Net profit (€)	142 000 000	159 000 000	-29 000 000	92 000 000	113 000 000	66 000 000	105 000 000
Turnover growth rate (%)	-9,4	-2,9	-9,4	-6,7	15,6	-5,2	-
Ebitda margin rate (%)	12,7	11,9	5,8	4,4	6	-	-
Operating margin rate (%)	11,1	10,7	9,7	4,4	7,7	-	-
Working Capital (turnover days)	125,7	133	104,2	-26,5	-16,5	-	-
Working Capital requirements (turnover days)	16,4	38,3	33,8	-7,2	2,9	-	-
Net margin (%)	9	9,1	-1,6	4,6	5,3	-	-
Added value / Turnover (%)	29,6	29,7	174,2	22,6	176,9	-	-
Wages and social charges (€)	229 000 000	253 000 000	-296 000 000	383 000 000	-308 000 000	-292 000 000	-
Salaries / Turnover (%)	14,5	14,5	-16,5	19,3	-14,5	-	-

Company Managers:

Position	First Name	Last Name	Age
Président du conseil d'administration, Directeur général, Administrateur	Audrey	DUVAL	45
Directeur général délégué	Jean-Marc	LACROIX	53
Directeur général délégué	Emmanuelle	FOUCHS	56